What about the company Vertex didn’t buy?

Vertex Pharmaceuticals’ decision to pay $4.9 billion for Alpine Immune Sciences cast a spotlight on the severe kidney disease IgA nephropathy — and, by extension, a company called Vera Therapeutics.